Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pitts

Showing results (211-220 of 231) with videos related to

Pageof 24
Sort By:
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Bioorganic & Medicinal Chemistry Letters|November 20, 2010
Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritisAlaric J Dyckman, Charles M Langevine, Claude Quesnelle, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2009
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritisKathleen M Gillooly, Mark A Pattoli, Tracy L Taylor, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery of highly potent, selective, covalent inhibitors of JAK3James Kempson, Damaso Ovalle, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Blood|January 31, 2016
Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2Erik B van den Akker, Steven J Pitts, Joris Deelen, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Pageof 24

Showing results (211-220 of 231) with videos related to

Sort By:
Pageof 24
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Bioorganic & Medicinal Chemistry Letters|November 20, 2010
Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritisAlaric J Dyckman, Charles M Langevine, Claude Quesnelle, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2009
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritisKathleen M Gillooly, Mark A Pattoli, Tracy L Taylor, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery of highly potent, selective, covalent inhibitors of JAK3James Kempson, Damaso Ovalle, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Blood|January 31, 2016
Uncompromised 10-year survival of oldest old carrying somatic mutations in DNMT3A and TET2Erik B van den Akker, Steven J Pitts, Joris Deelen, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Pageof 24